{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-039115","form_type":"8-K","ticker":"SNWV","cik":"0001417663","company_name":"SANUWAVE Health, Inc.","filed_at":"2025-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.938215+00:00","generated_at":"2026-05-17T16:16:24.074004+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sanuwave Q2 revenue $10.2M (+42% YoY), adjusted EBITDA $3.4M; guides Q3 $12-12.7M","bullets":["Q2 2025 revenue $10.2M, +42% YoY from $7.2M; gross margin 78.3% vs 73.2%.","GAAP operating income $1.9M (incl $1.1M stock comp) vs $2.0M prior; adjusted EBITDA $3.4M vs $1.5M.","Sold 116 UltraMist systems in Q2 (vs 72 Q2 2024); consumables revenue $6.4M, +37% YoY.","Q3 2025 revenue guidance $12-12.7M; full-year 2025 reaffirmed $48-50M (47-53% growth).","CEO says full national sales coverage achieved mid-July, aiming for breakout performance in Q4 2025 and 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-039115","json":"https://secwatch.observer/filing/0001628280-25-039115.json","markdown":"https://secwatch.observer/filing/0001628280-25-039115.md","text":"https://secwatch.observer/filing/0001628280-25-039115.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1417663/000162828025039115/0001628280-25-039115-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1417663/000162828025039115/snwv-20250808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T16:16:24.074004+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}